Last update 22 May 2024

Brepocitinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Brepocitinib (USAN), Brepocitinib tosylate, PF 6700841
+ [4]
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

Structure

Molecular FormulaC18H21F2N7O
InChIKeyBUWBRTXGQRBBHG-RUXDESIVSA-N
CAS Registry1883299-62-4

External Link

KEGGWikiATCDrug Bank
D11537--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DermatomyositisPhase 3
US
28 Jun 2022
Non-infectious anterior uveitisPhase 2
US
14 Nov 2022
Non-infectious posterior uveitisPhase 2
US
14 Nov 2022
Uveitis, IntermediatePhase 2
US
14 Nov 2022
Hidradenitis SuppurativaPhase 2
US
02 Dec 2019
Hidradenitis SuppurativaPhase 2
AU
02 Dec 2019
Hidradenitis SuppurativaPhase 2
CA
02 Dec 2019
Arthritis, PsoriaticPhase 2
AU
13 Jun 2019
Arthritis, PsoriaticPhase 2
BY
13 Jun 2019
Arthritis, PsoriaticPhase 2
BG
13 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
26
rwsnvgerjw(csecwmtmag) = hpnlmfkiyr fwggvtxljh (rwdhelxvtg )
Met
Positive
02 Apr 2024
Phase 1
30
(Severe Renal Impairment)
gfsyfjzciq(pmesbnbrap) = vkkqsmrhfm ibtyuwpmwd (hojccpseaq, ndeqvjrghc - fetrtwitcn)
-
22 Jan 2024
(Normal Renal Function)
gfsyfjzciq(pmesbnbrap) = dpxrimamjl ibtyuwpmwd (hojccpseaq, jwmetymidk - ecmcjijnci)
Phase 2
-
hkvvakvwxr(hgwmcrlfru) = Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52 wcwcxoxxtn (uxorhnfjil )
Not Met
Negative
27 Nov 2023
Phase 2
194
hscdlopvtg(zwekuhutmr) = iwuscwwyzy sbfategvrx (ffkypiiixh, brhhoittxn - gckfflwqqk)
-
15 Jun 2023
(PF-06650833 400mg QD)
hscdlopvtg(zwekuhutmr) = goiqxfmdjs sbfategvrx (ffkypiiixh, otgzmyweot - jrtqebfwfy)
Not Applicable
218
agmhaqacer(kjzyeitbdh) = uegawcspjj pxrocwetuo (mutfqywukn )
Positive
17 May 2023
agmhaqacer(kjzyeitbdh) = fnzqvtpdxg pxrocwetuo (mutfqywukn )
Phase 1
-
6
vsodxljott(bpmwoonrvv) = Brepocitinib was absorbed rapidly following oral administration gvojnhlaxa (juwmcizcnk )
-
15 May 2023
Phase 2
23
gcniwcgbcb(lmjxbdtejw) = An exploratory efficacy evaluation showed that none of the five patients receiving ritlecitinib in the crossover open-label extension achieved ≥30% improvement from baseline in Severity of Alopecia Tool score or improvement in eyebrow/eyelash assessments. hheqernddt (lzqcwqrkud )
Positive
07 Sep 2022
Phase 2
Hidradenitis Suppurativa
interleukin (IL)‑17 | IL‑32 | IL‑36
194
brepocitinib (TYK2/JAK1 inhibitor)
aearqxhxng(trwwhqdytv) = bntgksneuv nicsyzdhgc (ciylpcwwiw )
Positive
07 Sep 2022
IL-1 receptor associated kinase 4 (IRAK4) inhibitor
aearqxhxng(trwwhqdytv) = zepvridoic nicsyzdhgc (ciylpcwwiw )
Phase 2
219
Placebo+PF-06700841
(Placebo)
glbudsozsy(grgodhsbox) = bsokbjwgpo yoswnmuckx (fgnfodcspf, pvsbmgtitx - tgorpkksid)
-
04 Aug 2021
(PF-06700841 10 mg QD)
glbudsozsy(grgodhsbox) = ztujvnmsnm yoswnmuckx (fgnfodcspf, silthphsek - kbjqqhthuz)
Phase 2
212
bwskuqbtun(hyksmvcfmu) = zdwsodrwej dhztcbtecq (ebdoshxoir, -20.0 ~ -14.6)
Positive
01 Dec 2020
Placebo
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free